Neuropace
Quarterly Financials
| Values in thousands | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
Revenue | $26,588 | $27,354 | $23,520 | $22,524 |
Gross Profit | 20,578 | 21,168 | 18,132 | 17,342 |
EBITDA | -1,245 | -2,464 | -6,115 | -3,974 |
EBIT | -1,767 | -2,518 | -6,592 | -4,436 |
Net Income | -2,729 | -3,496 | -8,651 | -6,589 |
Net Change In Cash | 26,588 | 27,354 | 23,520 | 22,524 |
Free Cash Flow | 409 | -1,974 | -2,254 | -7,519 |
Cash | 21,692 | 20,648 | 22,857 | 27,019 |
Basic Shares | 32,722 | 33,134 | 32,863 | 31,480 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $99,986 | $79,906 | $65,421 | $45,520 |
Gross Profit | 77,220 | 59,085 | 48,122 | 32,493 |
EBITDA | -14,390 | -16,574 | -22,834 | -36,566 |
EBIT | -16,338 | -18,343 | -24,439 | -39,553 |
Net Income | -21,465 | -27,141 | -32,956 | -47,082 |
Net Change In Cash | 99,986 | 79,906 | 65,421 | 45,520 |
Cost of Revenue | -12,582 | |||
Free Cash Flow | -11,338 | -18,255 | -19,874 | -37,472 |
Cash | 21,692 | 13,430 | 18,058 | 6,605 |
Basic Shares | 32,722 | 29,126 | 25,851 | 24,594 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-12-31 | -$0.08 |
2025-09-30 | -$0.11 |
2025-06-30 | -$0.26 |
2025-03-31 | -$0.21 |
